(Information sent by the signatory company)

New Guided VCTE™ technology will increase efficiency, automation and standardization to make liver scanning seamless for all healthcare providers.

PARIS, May 22, 2024 /PRNewswire/ — Liver diseases currently cause two million deaths a year worldwide. This figure is expected to increase as obesity rates continue to rise globally. In response to the dire need to improve liver health monitoring, Echosens, a leader in liver health, is proud to announce that its new next-generation FibroScan® technology with guided vibration-controlled transient elastography (VCTE)™ is now available Worldwide. First launched in the United States in February, this next-generation FibroScan® is an essential tool in the battle against liver disease and meets the urgent need for accurate, efficient and non-invasive liver assessment, meeting the needs of healthcare professionals. health at the forefront of patient care.

Laurent Sandrin, founder and director of science and innovation at Echosens, highlights the crucial role of healthcare professionals in increasing detection rates, as three in 10 people worldwide are at risk of liver disease . “Given the projected increase in cases of liver disease, it is imperative to increase early detection rates. Our next-generation FibroScan®, featuring our patented Guided VCTE™ technology, is designed to be an indispensable and efficient tool for both diagnosis and for follow-up. We are committed to raising the standards of liver care for all patients, including obese patients, where screening was previously a challenge. We recognize and value the critical role of healthcare professionals in this process.

Guided VCTE™ leverages Echosens’ diagnostic expertise and provides accurate measurements of liver stiffness and steatosis. Healthcare professionals can use this sophisticated, easy-to-use technology for rapid, non-invasive assessments in diverse patient demographics, improving the speed of diagnosis and workflow.

“Our goal is to increase the accessibility of liver screening and we believe the key is to equip healthcare providers with technology that is accurate, simple and fast. As global rates of fatty liver disease associated with dysfunction increase (MAFLD) and steatohepatitis associated with metabolic dysfunction (MASH), our commitment to innovation and equipping healthcare providers with world-class technology is strengthened,” Sandrin continued.

Patients benefit from faster and more efficient assessments, reducing anxiety and discomfort. Immediate results also lead to more productive consultations at the point of care, minimizing delays in decision making and initiation of treatment.

“One of the notable benefits of the next-generation FibroScan® enhancement is the improved quality and consistency of results obtained. By incorporating Guided VCTE™, as healthcare providers, we can achieve more accurate and reliable assessments of liver stiffness , leading to better patient diagnostic outcomes,” said Louise Campbell, Nurse Practitioner and Clinical Director at Tawazun Health. “This is particularly important in the context of liver health and disease, as early detection and accurate monitoring are essential for optimal patient care.”

Key features of Guided VCTE™ include:

Guided VCTE™ represents the latest milestone in Echosens’ continued commitment to product innovation and evolution. As a global leader in liver health, Echosens provides healthcare professionals with a gold standard non-invasive solution for comprehensive liver management. This advancement simplifies disease diagnosis and management by making liver assessments more accessible and seamlessly integrated into practices.

Guided VCTE™ provides unparalleled precision and ease of use. As the first connected devices in the FibroScan® range, it features simplified cloud-based reporting and multiple features through the upcoming Liver Health Management Platform, an innovative cloud-based solution to improve patient management across the continuum of care. . Once again, after years of maintaining an exceptional track record of innovation, Echosens distinguishes itself from other imaging techniques, reaffirming its leading position in the industry.

To learn more about Echosens liver health solutions, visit echosens.com, and to learn about Guided VCTE™, visit here.

About Echosens

A pioneer in its field, Echosens, significantly changed the practice of liver evaluation with FibroScan®, the non-invasive solution for the comprehensive management of liver health. FibroScan® is recognized worldwide and validated by more than 4,200 peer-reviewed publications and more than 180 international guidelines. Echosens has made FibroScan® available in more than 127 countries, enabling millions of liver exams to be performed worldwide. https://www.echosens.com/

Logo – https://mma.prnewswire.com/media/2370966…

View original content: https://www.prnewswire.com/es/comunicados-de-prensa/transformando-la-salud-del-higado-fibroscan-de-proxima-generacion-de-echosens-disponible-en-todo-el-mundo-302152809.html